neurotoxicity - Page 1 | CARLAT PUBLISHING

Clinical Update

Tapering Antipsychotics

November 1, 2023

Charmi Patel Rao, MD, DFAACAP. Director of Psychiatric Services, Positive Development; Health Sciences Assistant Clinical Professor, Department of Psychiatry, Child and Adolescent Psychiatry; UCSD, San Diego, CA.

Dr. Patel Rao has no financial relationships with companies related to this material.

Antipsychotics offer remarkable, even lifesaving treatment for children and adolescents, however, their side effects include metabolic and neurologic problems, including neurotoxicity. This clinical update guides you through a rational process for employing these powerful medications when necessary but also reducing and discontinuing them when possible.

Getting Uncomfortable with Esketamine

January 13, 2020

Nolan Williams, MD

Nolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA. Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.

Exploring the Potential Neurotoxicity of Antipsychotics in Younger Populations

November 21, 2019

With all the existing concerns about use of antipsychotic medications, particularly in off label situations, should we be also concerned about the potential for neurotoxicity? In this article we break down the topic and make suggestions for thoughtful patient care.